PL3095441T3 - Oral vaccine fast-dissolving dosage form using starch - Google Patents

Oral vaccine fast-dissolving dosage form using starch

Info

Publication number
PL3095441T3
PL3095441T3 PL16178493T PL16178493T PL3095441T3 PL 3095441 T3 PL3095441 T3 PL 3095441T3 PL 16178493 T PL16178493 T PL 16178493T PL 16178493 T PL16178493 T PL 16178493T PL 3095441 T3 PL3095441 T3 PL 3095441T3
Authority
PL
Poland
Prior art keywords
starch
dosage form
oral vaccine
dissolving dosage
fast
Prior art date
Application number
PL16178493T
Other languages
Polish (pl)
Inventor
Wei Tian
Rosie Mclaughlin
Original Assignee
R.P. Scherer Technologies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R.P. Scherer Technologies, Llc filed Critical R.P. Scherer Technologies, Llc
Publication of PL3095441T3 publication Critical patent/PL3095441T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL16178493T 2010-10-08 2011-10-11 Oral vaccine fast-dissolving dosage form using starch PL3095441T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39123810P 2010-10-08 2010-10-08
EP16178493.9A EP3095441B1 (en) 2010-10-08 2011-10-11 Oral vaccine fast-dissolving dosage form using starch
EP11779263.0A EP2624815B8 (en) 2010-10-08 2011-10-11 Oral vaccine fast-dissolving dosage form using starch
PCT/US2011/055689 WO2012048333A1 (en) 2010-10-08 2011-10-11 Oral vaccine fast-dissolving dosage form using starch

Publications (1)

Publication Number Publication Date
PL3095441T3 true PL3095441T3 (en) 2021-06-14

Family

ID=44908091

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16178493T PL3095441T3 (en) 2010-10-08 2011-10-11 Oral vaccine fast-dissolving dosage form using starch

Country Status (17)

Country Link
US (1) US9956169B2 (en)
EP (2) EP3095441B1 (en)
JP (2) JP6061859B2 (en)
KR (1) KR101751964B1 (en)
CN (2) CN103347494A (en)
AR (1) AR083361A1 (en)
AU (1) AU2011312107B2 (en)
BR (1) BR112013009255B1 (en)
CA (1) CA2813146C (en)
DK (2) DK2624815T3 (en)
ES (2) ES2842290T3 (en)
HU (1) HUE052853T2 (en)
MX (2) MX386380B (en)
PL (1) PL3095441T3 (en)
PT (1) PT3095441T (en)
RU (2) RU2639447C2 (en)
WO (1) WO2012048333A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095441B1 (en) * 2010-10-08 2020-12-02 R.P. Scherer Technologies, LLC Oral vaccine fast-dissolving dosage form using starch
US10272038B2 (en) 2013-12-02 2019-04-30 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
TWI745278B (en) * 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 Reduced foaming vaccine compositions
CN104530489B (en) * 2015-02-05 2017-07-07 湖南尔康制药股份有限公司 A kind of starch film-forming composition for being instantly dissolved in water
CN109224191A (en) * 2018-07-23 2019-01-18 西安交通大学医学院第附属医院 A kind of aseptic transfusion port auxiliary implanted device for venous transfusion
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
PL3791395T3 (en) 2019-07-31 2022-01-24 Catalent U.K. Swindon Zydis Limited Density flow meter for pharmaceutical formulation dosing
CN116194085A (en) 2020-09-17 2023-05-30 康特伦英国斯温顿捷迪斯有限公司 Use of dosage forms based on surfactants and high molecular weight fish gelatin for improving flow properties
US20230364013A1 (en) 2020-10-08 2023-11-16 Catalent U.K. Swindon Zydis Limited Stable oral dispersible formulation for epinephrine
EP4243796A4 (en) 2020-11-16 2025-01-22 Orcosa Inc. ENHANCED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2026024894A2 (en) 2024-07-24 2026-01-29 De Alba Jorge Sublingual formulations of a peptide derived from chaperonin 60.1 and related methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IT1250421B (en) 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
EP0688205A1 (en) * 1993-03-11 1995-12-27 Secretech, Inc. Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
WO1997013531A1 (en) * 1995-10-13 1997-04-17 Zynaxis, Inc. Solid, orally administrable viral vaccines and methods of preparation
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1579851A3 (en) * 1997-08-29 2009-09-02 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
HK1046004B (en) * 1999-11-12 2013-11-08 Fibrogen, Inc. Recombinant gelatins
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
PT1501534E (en) * 2002-05-07 2006-09-29 Ferring Bv PHARMACEUTICAL FORMULATIONS
EP1551376A4 (en) * 2002-08-12 2010-10-06 Dynavax Tech Corp IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US8012505B2 (en) * 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
JP2006525308A (en) * 2003-05-02 2006-11-09 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Fast-dissolving oral consumable film containing modified starch with improved heat and moisture resistance
EP1670509A4 (en) 2003-09-03 2007-10-31 Dendritherapeutics Inc Multiplex vaccines
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20110129438A1 (en) 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
CN103751091B (en) * 2008-02-28 2017-08-25 R·P·舍勒科技有限责任公司 The method for minimizing polymorphism
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
WO2010036970A2 (en) * 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
KR101074271B1 (en) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 Fast dissolving oral dosage form containing steviosides as a taste masking agent
US8545879B2 (en) * 2009-08-31 2013-10-01 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam
TR201902233T4 (en) * 2009-10-30 2019-03-21 Ix Biopharma Ltd Fast dissolving solid dosage form.
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US20130108762A1 (en) * 2010-07-08 2013-05-02 Xiaoqun Mo Confection with gelatin complex
EP3095441B1 (en) * 2010-10-08 2020-12-02 R.P. Scherer Technologies, LLC Oral vaccine fast-dissolving dosage form using starch

Also Published As

Publication number Publication date
CN103347494A (en) 2013-10-09
WO2012048333A1 (en) 2012-04-12
US9956169B2 (en) 2018-05-01
MX386380B (en) 2025-03-18
ES2602506T3 (en) 2017-02-21
AU2011312107A1 (en) 2013-05-02
RU2017137357A (en) 2019-04-25
ES2842290T3 (en) 2021-07-13
JP2013539766A (en) 2013-10-28
RU2013119946A (en) 2014-11-20
MX2013003875A (en) 2013-06-24
AU2011312107B2 (en) 2016-06-23
DK2624815T3 (en) 2016-11-07
JP6403738B2 (en) 2018-10-10
DK3095441T3 (en) 2021-01-11
BR112013009255A2 (en) 2016-07-26
EP2624815A1 (en) 2013-08-14
JP2016199605A (en) 2016-12-01
US20120087944A1 (en) 2012-04-12
EP2624815B1 (en) 2016-08-10
KR101751964B1 (en) 2017-06-28
CA2813146A1 (en) 2012-04-12
BR112013009255B1 (en) 2021-02-23
RU2017137357A3 (en) 2019-04-25
RU2639447C2 (en) 2017-12-21
AR083361A1 (en) 2013-02-21
HUE052853T2 (en) 2021-05-28
PT3095441T (en) 2021-01-14
CA2813146C (en) 2018-12-18
MX347101B (en) 2017-04-12
JP6061859B2 (en) 2017-01-18
EP3095441A1 (en) 2016-11-23
CN108434089B (en) 2020-06-16
EP3095441B1 (en) 2020-12-02
EP2624815B8 (en) 2016-09-21
KR20140091461A (en) 2014-07-21
CN108434089A (en) 2018-08-24
HK1253541A1 (en) 2019-06-21

Similar Documents

Publication Publication Date Title
PT3095441T (en) Oral vaccine fast-dissolving dosage form using starch
EP2563346A4 (en) Solid oral dosage forms comprising tadalafil
GB0909680D0 (en) Dosage form
EP2521515A4 (en) Oral orthosis
ZA201209156B (en) Therapeutic oral composition
ZA201304158B (en) Dosage form
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
PL2995219T5 (en) Oral care products
ZA201304709B (en) A pharmaceutical dosage form
PL2550938T3 (en) Oral hygiene device
ZA201206666B (en) Oral care composition
GB201010193D0 (en) Medicinal use
ZA201206301B (en) Oral care composition
IL223311A0 (en) Oral dosage forms of bendamustine
GB0822124D0 (en) Oral dosage form
IL226340A0 (en) Dental devices
EP2474294A4 (en) Preparation for oral administration
GB0922537D0 (en) Pharmaceutical preparation
GB201018760D0 (en) An oral dosage form
GB0906003D0 (en) Oral drug formulation
PH32010000669S1 (en) Oral care implement
PH32010000661S1 (en) Oral care implement
ZA201201424B (en) Pharmaceutical dosage form
GB201018917D0 (en) Dosage form
GB201011271D0 (en) Dosage Form